89bio, Inc.
Clinical trials sponsored by 89bio, Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing therapies for liver and metabolic diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug aims to tame dangerous fat levels in blood
Disease control CompletedThis study tested a drug called pegozafermin in 369 adults with severe hypertriglyceridemia, a condition where blood fat levels are dangerously high. Participants received either the drug or a placebo for 26 weeks. The main goal was to see if the drug could safely lower triglycer…
Phase 3 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug shows promise for reversing liver damage in NASH patients
Disease control CompletedThis study tested a new drug called BIO89-100 (Pegozafermin) in 222 adults with NASH, a serious fatty liver disease with liver scarring. Participants received weekly injections of the drug or a placebo for about 6 months. The goal was to see if the drug could reduce liver inflamm…
Phase 2 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC